GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nextbiomedical Co Ltd (XKRX:389650) » Definitions » Net Income From Continuing Operations

Nextbiomedical Co (XKRX:389650) Net Income From Continuing Operations : ₩-1,614 Mil (TTM As of Mar. 2025)


View and export this data going back to 2024. Start your Free Trial

What is Nextbiomedical Co Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Nextbiomedical Co's net income from continuing operations for the three months ended in Mar. 2025 was ₩-421 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2025 was ₩-1,614 Mil.

Nextbiomedical Co Net Income From Continuing Operations Historical Data

The historical data trend for Nextbiomedical Co's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nextbiomedical Co Net Income From Continuing Operations Chart

Nextbiomedical Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Net Income From Continuing Operations
-24,477.36 -16,644.94 -5,731.85 -7,521.51 2,859.56

Nextbiomedical Co Quarterly Data
Dec20 Dec21 Dec22 Mar23 Sep23 Dec23 Mar24 Sep24 Dec24 Mar25
Net Income From Continuing Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only -2,856.67 -354.97 -1,336.90 143.51 -420.66

Nextbiomedical Co Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-1,614 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nextbiomedical Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nextbiomedical Co Ltd (XKRX:389650) » Definitions » Net Income From Continuing Operations
Comparable Companies
XKRX:397030 XKRX:475960 XKRX:228760 XKRX:334970 XKRX:078160 XKRX:011000 XKRX:140610 XKRX:064550 XKRX:372320 XKRX:086820 VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
N/A
Address
Venture-ro, No. 6, 100 beongil, Yeonsu-gu, Incheon, KOR
Website
https://www.nextbiomedical.co.kr/kr
Nextbiomedical Co Ltd is an bio-solution company. The company develops and commercializes therapeutic agents for treating diseases based on polymer and drug delivery system technology. The company has developed products that include endoscopic hemostatic agents, vascular embolic microspheres, and others.

Nextbiomedical Co Headlines

No Headlines